Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) Expected to Announce Quarterly Sales of $460,000.00

Analysts expect Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) to report $460,000.00 in sales for the current quarter, Zacks reports. Three analysts have provided estimates for Infinity Pharmaceuticals’ earnings, with the lowest sales estimate coming in at $200,000.00 and the highest estimate coming in at $690,000.00. Infinity Pharmaceuticals posted sales of $430,000.00 in the same quarter last year, which would indicate a positive year-over-year growth rate of 7%. The firm is expected to report its next earnings results on Monday, May 10th.

According to Zacks, analysts expect that Infinity Pharmaceuticals will report full year sales of $2.11 million for the current fiscal year, with estimates ranging from $800,000.00 to $3.44 million. For the next year, analysts expect that the business will post sales of $3.42 million, with estimates ranging from $800,000.00 to $7.22 million. Zacks Investment Research’s sales calculations are an average based on a survey of analysts that cover Infinity Pharmaceuticals.

Infinity Pharmaceuticals (NASDAQ:INFI) last posted its quarterly earnings results on Monday, March 15th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of ($0.16). Infinity Pharmaceuticals had a negative return on equity of 1,358.77% and a negative net margin of 2,592.65%.

A number of research firms have issued reports on INFI. B. Riley lowered their price target on Infinity Pharmaceuticals from $8.00 to $7.00 and set a “buy” rating for the company in a research report on Tuesday, March 23rd. Wells Fargo & Company boosted their price target on Infinity Pharmaceuticals from $2.00 to $4.00 and gave the company an “equal weight” rating in a research report on Tuesday, March 23rd. Oppenheimer upped their target price on Infinity Pharmaceuticals from $5.50 to $9.00 and gave the stock an “outperform” rating in a research report on Thursday, February 11th. Piper Sandler assumed coverage on Infinity Pharmaceuticals in a research report on Thursday, February 25th. They issued an “overweight” rating and a $7.00 target price for the company. Finally, Truist assumed coverage on Infinity Pharmaceuticals in a research report on Thursday, March 18th. They issued a “buy” rating and a $12.00 target price for the company. Two investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Infinity Pharmaceuticals has a consensus rating of “Buy” and a consensus price target of $8.31.

In related news, major shareholder Bvf Partners L. P/Il sold 5,848,520 shares of the stock in a transaction dated Friday, January 22nd. The stock was sold at an average price of $4.14, for a total value of $24,212,872.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 13.77% of the company’s stock.

Hedge funds and other institutional investors have recently made changes to their positions in the business. Private Wealth Advisors Inc. acquired a new stake in Infinity Pharmaceuticals during the fourth quarter valued at approximately $25,000. Morgan Stanley raised its stake in Infinity Pharmaceuticals by 268.9% during the third quarter. Morgan Stanley now owns 35,251 shares of the biotechnology company’s stock valued at $41,000 after buying an additional 25,695 shares in the last quarter. JPMorgan Chase & Co. raised its stake in Infinity Pharmaceuticals by 165,024.0% during the fourth quarter. JPMorgan Chase & Co. now owns 41,281 shares of the biotechnology company’s stock valued at $88,000 after buying an additional 41,256 shares in the last quarter. Callan Capital LLC acquired a new stake in Infinity Pharmaceuticals during the fourth quarter valued at approximately $155,000. Finally, BlackRock Inc. raised its stake in Infinity Pharmaceuticals by 0.6% during the fourth quarter. BlackRock Inc. now owns 976,446 shares of the biotechnology company’s stock valued at $2,071,000 after buying an additional 5,748 shares in the last quarter. Hedge funds and other institutional investors own 46.66% of the company’s stock.

INFI stock traded up $0.17 during trading on Monday, reaching $3.51. 35,600 shares of the stock traded hands, compared to its average volume of 3,897,280. The business’s 50 day moving average price is $3.27 and its 200-day moving average price is $2.43. Infinity Pharmaceuticals has a 52-week low of $0.78 and a 52-week high of $5.98. The firm has a market capitalization of $311.13 million, a PE ratio of -4.70 and a beta of 2.40.

Infinity Pharmaceuticals Company Profile

Infinity Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing novel medicines for people with cancer. It offers IPI-549, an orally administered, clinical-stage, immuno-oncology product candidate that selectively inhibits the enzyme phosphoinositide-3-kinase-gamma Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma), which is in Phase 1/1b clinical study.

Read More: What is a Candlestick Chart?

Get a free copy of the Zacks research report on Infinity Pharmaceuticals (INFI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com